Jiangsu Hengrui Pharmaceuticals(600276.SH): Clinical trial applications for injection SHR-A1811 and injection SHR-9839 approved.

16/01/2025

GMT Eight

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiaries, Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Jiangsu Hengrui Pharmaceuticals Co., Ltd., have received approval from the National Medical Products Administration for the clinical trial of injectable drugs SHR-A1811 and SHR-9839. The clinical trials will be conducted in the near future.

China Pacific Insurance subsidiary Taikang Life Insurance's total premium income for the year 2024 reached 238.823 billion yuan, a year-on-year increase of 2.4%.

Shanghai PECHEM (00338) spent HK$2.5558 million to repurchase 2.25 million shares on January 16th.

Contact: contact@gmteight.com

Jiangsu Hengrui Pharmaceuticals(600276.SH): Clinical trial applications for injection SHR-A1811 and injection SHR-9839 approved.

RECOMMEND

Shenzhen Worldunion Group Incorporated (002285.SZ) elects Chen Weicheng as Chairman.

Strong Petro (00852) appointed Li Haiqiang as Chief Domestic Affairs Coordinator.

Haitian Water Group, the controlling shareholder, plans to increase its holdings in the company by 100 million to 120 million yuan.